Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen‐reduction technology

Girard, Yvette A.; Maria, Felicia Santa; Lanteri, Marion C.

doi:10.1111/trf.15673

Cited by 4 publications

(6 citation statements)

References 31 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Flaviviruses have ranked high on the priority list of agents posing a threat to the blood supply . Their sensitivity to inactivation by amotosalen/UVA was first demonstrated for West Nile virus (WNV) and dengue virus, and was further confirmed with Zika virus (ZIKV) and yellow fever virus (YFV) . The LRF for all emerging flaviviruses tested is >4.0 log in plasma and PC‐PAS or PC‐100% (Table ).…”

Section: Resultsmentioning

confidence: 99%

“…The reemergence of YFV in Angola in 2015 and in large areas of Brazil in 2017‐2018, resulted in the deferral of thousands of platelet donors for several weeks following vaccination with live virus. The amotosalen/UVA PRT may be considered in the future as an alternative approach to deferrals during massive YFV vaccination campaigns . In Europe, the expansion of Aedes species and Culex species mosquitoes and associated dengue virus, CHIKV, and WNV outbreaks have led to more deferrals and blood screening requirements.…”

Section: Discussionmentioning

confidence: 99%

“…The amotosalen/UVA PRT may be considered in the future as an alternative approach to deferrals during massive YFV vaccination campaigns. 85 In Europe, the expansion of Aedes species and Culex species mosquitoes and associated dengue virus, CHIKV, and WNV outbreaks have led to more deferrals and blood screening requirements. The experience in the United States has also shown that WNV TTIs continue to occur despite WNV ID-NAT screening.…”

Section: Discussionmentioning

confidence: 99%

“…fever virus (YFV). 85 The LRF for all emerging flaviviruses tested is >4.0 log in plasma and PC-PAS or PC-100% (Table 1).…”

Section: Inactivation Of Flavivirusesmentioning

confidence: 97%

See 3 more Smart Citations

Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light

et al. 2020

Self Cite

View full text Add to dashboard Cite

BACKGROUND The INTERCEPT Blood System pathogen reduction technology (PRT), which uses amotosalen and ultraviolet A light treatment (amotosalen/UV‐PRT), inactivates pathogens in plasma and platelet components (PCs). This review summarizes data describing the inactivation efficacy of amotosalen/UVA‐PRT for a broad spectrum of viruses and parasites. METHODS Twenty‐five enveloped viruses, six nonenveloped viruses (NEVs), and four parasites species were evaluated for sensitivity to amotosalen/UVA‐PRT. Pathogens were spiked into plasma and PC at high titers. Samples were collected before and after PRT and assessed for infectivity with cell cultures or animal models. Log reduction factors (LRFs) were defined as the difference in infectious titers before and after amotosalen/UV‐PRT. RESULTS LRFs of ≥4.0 log were reported for 19 pathogens in plasma (range, ≥4.0 to ≥7.6), 28 pathogens in PC in platelet additive solution (PC‐PAS; ≥4.1‐≥7.8), and 14 pathogens in PC in 100% plasma (PC‐100%; (≥4.3‐>8.4). Twenty‐five enveloped viruses and two NEVs were sensitive to amotosalen/UV‐PRT; LRF ranged from >2.9 to ≥7.6 in plasma, 2.4 or greater to greater than 6.9 in PC‐PAS and >3.5 to >6.5 in PC‐100%. Infectious titers for four parasites were reduced by >4.0 log in all PC and plasma (≥4.9 to >8.4). CONCLUSION Amotosalen/UVA‐PRT demonstrated effective infectious titer reduction for a broad spectrum of viruses and parasites. This confirms the capacity of this system to reduce the risk of viral and parasitic transfusion‐transmitted infections by plasma and PCs in various geographies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…fever virus (YFV). 85 The LRF for all emerging flaviviruses tested is >4.0 log in plasma and PC-PAS or PC-100% (Table 1).…”

Section: Inactivation Of Flavivirusesmentioning

confidence: 97%

See 2 more Smart Citations

Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pathogen reduction technologies (PRT) are being increasingly used to ensure safety of critical blood components such as plasma and platelets: progressive deployment has been often accelerated by emerging epidemics, such as Zika virus, 1,2 Dengue virus, 3,4 Chikungunya virus, 5 Yellow fever virus, 6 Middle East respiratory syndrome coronavirus 7 and severe acute respiratory syndrome (SARS)‐1 coronavirus 8 . Different PRT brands exist on the market, having interstrand cross‐links and fragmentation of nucleic acids in both blood cells and different classes of pathogens as the common mechanism of action (MOA): when photochemicals are used, DNA fragmentation is triggered by ultraviolet irradiation (photoactivation) of the active ingredient 9 : formation of adducts between the photochemical and nucleic acid block replication, transcription and translation.…”

Section: Introductionmentioning

confidence: 99%

Molecular validation of pathogen‐reduction technologies using rolling‐circle amplification coupled with real‐time PCR for torquetenovirus DNA quantification

Focosi¹,

Macera

Spezia

et al. 2021

Transfusion Medicine

View full text Add to dashboard Cite

Background Pathogen reduction technologies (PRT) based on nucleic‐acid damaging chemicals and/or irradiation are increasingly being used to increase safety of blood components against emerging pathogens, such as convalescent plasma in the ongoing COVID‐19 pandemic. Current methods for PRT validation are limited by the resources available to the blood component manufacturer, and quality control rely over pathogen spiking and hence invariably require sacrifice of the tested blood units: quantitative real‐time PCR is the current pathogen detection method but, due to the high likelihood of detecting nonviable fragments, requires downstream pathogen culture. We propose here a new molecular validation of PRT based on the highly prevalent human symbiont torquetenovirus (TTV) and rolling circle amplification (RCA). Materials and methods Serial apheresis plasma donations were tested for TTV before and after inactivation with Intercept® PRT using real‐time quantitative PCR (conventional validation), RCA followed by real‐time PCR (our validation), and reverse PCR (for cross‐validation). Results While only 20% of inactivated units showed significant decrease in TTV viral load using real‐time qPCR, all donations tested with RCA followed by real‐time PCR showed TTV reductions. As further validation, 2 units were additionally tested with reverse PCR, which confirmed absence of entire circular genomes. Discussion We have described and validated a conservative and easy‐to‐setup protocol for molecular validation of PRT based on RCA and real‐time PCR for TTV.

show abstract

Ultrafast-UV laser integrating cavity device for inactivation of SARS-CoV-2 and other viruses

Ambardar

Howell

Mayilsamy

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Ultraviolet (UV) irradiation-based methods used for viral inactivation have provided an important avenue targeting severe acute respiratory-syndrome coronavirus-2 (SARS-CoV-2) virus. A major problem with state-of-the-art UV inactivation technology is that it is based on UV lamps, which have limited efficiency, require high power, large doses, and long irradiation times. These drawbacks limit the use of UV lamps in air filtering systems and other applications. To address these limitations, herein we report on the fabrication of a device comprising a pulsed nanosecond 266 nm UV laser coupled to an integrating cavity (LIC) composed of a UV reflective material, polytetrafluoroethylene. Previous UV lamp inactivation cavities were based on polished walls with specular reflections, but the diffuse reflective UV ICs were not thoroughly explored for virus inactivation. Our results show that LIC device can inactivate several respiratory viruses including SARS-CoV-2, at ~ 1 ms effective irradiation time, with > 2 orders of magnitude higher efficiency compared to UV lamps. The demonstrated 3 orders of magnitude cavity enhancement relative to direct exposure is crucial for the development of efficient real-time UV air and water purification systems. To the best of our knowledge this is the first demonstration of LIC application for broad viral inactivation with high efficiency.

show abstract

Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen‐reduction technology

Cited by 4 publications

References 31 publications

Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light

Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light

Molecular validation of pathogen‐reduction technologies using rolling‐circle amplification coupled with real‐time PCR for torquetenovirus DNA quantification

Ultrafast-UV laser integrating cavity device for inactivation of SARS-CoV-2 and other viruses

Contact Info

Product

Resources

About